Mar 3, 2027Research
— / —No executable quote
Research candidateOpen
Ozekibart
Inhibrx Biosciences · unresectable or metastatic conventional chondrosarcomaApr 14, 2027 target
Will the FDA approve Ozekibart for unresectable or metastatic conventional chondrosarcoma?
INBX-YES/ USDC
Outcome claim / Research candidate
Executable price
—
Change across observed prices in this windowImplied YES probability—Price-based, not a clinical forecast
Market not listed
No market price yet.
This program has no funded pool or observed trading history. Start with the evidence, or explore a clearly labeled scenario.
0 trading observationsNo live price feed
YES —NO —
This chart stays empty until observations exist. Research status is not an approval probability. A sandbox session creates a separate virtual price history.
Rx-INBX-2704 / Evidence
UnlistedPool price—No deployed pool
Dated model P(YES)—No dated model artifact
Days to sponsor target163Date-only guidance
Source publishedJun 15, 2026
Research snapshotOct 28, 2026
FDA targetApr 14, 2027
AntibodyNCT04950075
A pool price describes trading inventory; a model estimates an outcome. Neither a live price nor a dated forecast is available for this unlisted catalyst.
Program overview
Filing reports BLA acceptance for ozekibart in conventional chondrosarcoma and an April 14, 2027 FDA target.
THERAPEUTIC AREAOncology
DRUG / PROGRAMOzekibart
INDICATIONunresectable or metastatic conventional chondrosarcoma
REGULATORY TARGETApril 14, 2027
Agent model / unavailable
No reviewed probability or reasoning artifact is available. A neutral pool opening is not a clinical base rate.
What matters
- Distinguish conventional histology and disease stage; review updated safety and any changed FDA timetable before publication.
- Approval, the stock price and commercial success are different outcomes. A claim only pays on its specified event.
- Future program funding and tokenized financing require separate rights and contracts. An event claim gives no equity, royalty or drug IP.